Subcutaneous trastuzumab was observed to have a safety profile and efficacy similar to standard IV administration, offering a viable treatment alternative, according to study results published ...

For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior to the standard intravenous formulation.

"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...

Results of the multicenter, crossover PrefHER trial, which randomized 240 women undergoing neoadjuvant or adjuvant treatment for HER-positive breast cancer to 4 cycles each of IV trastuzumab or SC ...

The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

1 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011 ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...

Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC ...

Use of this radiotracer-infused trastuzumab allows direct visualization of trastuzumab distribution in single photon emission computed tomography (SPECT) images. The team delivered a total of 20 ...